Role of endocrine therapy in early-stage HR-positive breast cancer

Teaching Cases Focused on the Role of Endocrine-Based Therapy in the Management of Breast CancerПодробнее

BBCC 2024 - Hall A - Day 1 - The not so Easy Luminal Breast CancerПодробнее

Data + Perspectives: HR-Positive Breast Cancer (1 of 5)Подробнее

Presentation: Hormone Receptor-Positive Metastatic BC Harboring PI3K/AKT/PTEN Pathway AbnormalitiesПодробнее

Oncology Today with Dr Neil Love: Overcoming Endocrine Resistance in ER-Positive Metastatic Breas...Подробнее

Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring...Подробнее

Foundation Frontiers: Advanced Breast Cancer - Updates to HR+/HER2- Treatment LandscapeПодробнее

Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Ne...Подробнее

Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 InhibitionПодробнее

Staying on endocrine therapy longer to reduce risk of breast cancer recurrenceПодробнее

Optimizing Early Breast Cancer Outcomes in the Community Setting: An Expert Review of Emerging Th...Подробнее

Advancements in Care for Early-stage Breast Cancer 2024Подробнее

NATALEE - Addition of Ribociclib to Endocrine Therapy in Adjuvant Settings - Breast Cancer ESMO 2024Подробнее

Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Ne...Подробнее

Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast CancerПодробнее

Individualizing the Selection of First-Line Therapy for Patients with HR-Positive Metastatic BCПодробнее

Live Webinar - Breast Cancer Deep Dive 2024 | 07th & 08th August 2024 at 07:00 PM IST OnwardsПодробнее

Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast CancerПодробнее

First-Line Endocrine-Based Therapy for Patients with HR+, HER2-Negative Metastatic Breast CancerПодробнее